WO2022002065A9 - 抗cd40抗体或抗原结合片段及其应用 - Google Patents

抗cd40抗体或抗原结合片段及其应用 Download PDF

Info

Publication number
WO2022002065A9
WO2022002065A9 PCT/CN2021/103184 CN2021103184W WO2022002065A9 WO 2022002065 A9 WO2022002065 A9 WO 2022002065A9 CN 2021103184 W CN2021103184 W CN 2021103184W WO 2022002065 A9 WO2022002065 A9 WO 2022002065A9
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibody
binding fragment
preparation
tumor cell
Prior art date
Application number
PCT/CN2021/103184
Other languages
English (en)
French (fr)
Other versions
WO2022002065A1 (zh
Inventor
张慧
黄贤明
岳睿
陈振埕
汪志炜
陈俊有
李胜峰
Original Assignee
百奥泰生物制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百奥泰生物制药股份有限公司 filed Critical 百奥泰生物制药股份有限公司
Publication of WO2022002065A1 publication Critical patent/WO2022002065A1/zh
Publication of WO2022002065A9 publication Critical patent/WO2022002065A9/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了一种抗CD40抗体或抗原结合片段，所述抗体或抗原结合片段特异性结合CD40，能够活化抗原呈递细胞，刺激抗原呈递细胞释放细胞因子，诱导肿瘤细胞凋亡，抑制肿瘤细胞增殖。还提供上述抗体或抗原结合片段在制备用于治疗或改善CD40相关疾病的药物中的应用，或在制备用于诊断CD40相关疾病的试剂盒中的应用。
PCT/CN2021/103184 2020-06-30 2021-06-29 抗cd40抗体或抗原结合片段及其应用 WO2022002065A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010610151 2020-06-30
CN202010610151.4 2020-06-30

Publications (2)

Publication Number Publication Date
WO2022002065A1 WO2022002065A1 (zh) 2022-01-06
WO2022002065A9 true WO2022002065A9 (zh) 2022-02-24

Family

ID=78990129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/103184 WO2022002065A1 (zh) 2020-06-30 2021-06-29 抗cd40抗体或抗原结合片段及其应用

Country Status (2)

Country Link
CN (1) CN113861292A (zh)
WO (1) WO2022002065A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117229396A (zh) * 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
RU2425841C2 (ru) * 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
CN109265552A (zh) * 2012-10-30 2019-01-25 埃派斯进有限公司 抗-cd40抗体及其使用方法
MX2017015143A (es) * 2015-05-29 2018-03-28 Abbvie Inc Anticuerpos anti-cd40 y sus usos.
US10544229B2 (en) * 2015-09-30 2020-01-28 Janssen Biotech, Inc. Agonistic antibodies specifically binding CD40 and methods of use
US20200048358A1 (en) * 2017-05-02 2020-02-13 Alligator Bioscience Ab Bispecific antibody against ox40 and ctla-4
CN109384845B (zh) * 2017-08-14 2022-06-21 中国科学院上海营养与健康研究所 一种cd40单克隆抗体、其制备方法及其应用
WO2019057792A1 (en) * 2017-09-19 2019-03-28 Mab Discovery Gmbh CD40 ANTIBODY AGONISTS
CN108913721A (zh) * 2018-07-23 2018-11-30 安徽古生物科技有限公司 表达cd40抗体的慢病毒载体、car-t细胞的构建方法及应用
CN109678959B (zh) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 抗cd40抗体及其应用

Also Published As

Publication number Publication date
WO2022002065A1 (zh) 2022-01-06
CN113861292A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
WO2002028480A3 (en) Methods of therapy for b-cell malignancies
MX2021013608A (es) Composiciones y métodos de fabricacion de celulas t.
WO2005044304A3 (en) Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044855A3 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2006044860A3 (en) Thiadiazole compounds and methods of use
NZ603245A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
WO2007117600A3 (en) Combination therapy for treating autoimmune diseases
WO2004064728A3 (en) Use of specific tetracycline compounds in therapy
WO2022002065A9 (zh) 抗cd40抗体或抗原结合片段及其应用
WO2010115868A3 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
WO2012044933A3 (en) B and t lymphocyte attenuator marker for use in adoptive t-cell therapy
EP1680141B8 (en) Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2007011372A3 (en) Therapeutic and prognostic factor yy1 in human cancer
NZ594784A (en) Therapy with CD4 binding peptides and radiation
WO2003086470A3 (en) Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MX2021015401A (es) Terapia de combinacion que comprende un conjugado de farmacoanticuerpo anti-cd25 y otro agente.
IL257929B1 (en) Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells
Check et al. Sympathetic nervous system disorder of women that leads to pelvic pain and symptoms of interstitial cystitis may be the cause of severe backache and be very responsive to medical therapy rather than surgery despite the presence of herniated discs
MX2023001815A (es) Metodos y composiciones de fabricacion de celulas t.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21831789

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 21831789

Country of ref document: EP

Kind code of ref document: A1